Getting patients to goal: Optimal targets and therapies

International Journal of Clinical Practice

Volumn 60, Issue SUPPL. 150, 2006, Pages 1-2

  Fujita, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; NITRENDIPINE;

ASIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSENSUS; EDITORIAL; EUROPE; HEALTH ECONOMICS; HEALTH PRACTITIONER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL PRACTICE; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; STROKE; SYSTEMATIC REVIEW; UNITED STATES;

EID: 33748949747     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01114.x     Document Type: Editorial

References (2)

1. Schrader J, Luders S, Kulschewski A et.al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study. Stroke 2005; 36: 1218-26.
2. Staessen, JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.